Obstetrics & Gynecology

Skip Navigation LinksHome > August 2013 - Volume 122 - Issue 2, PART 2 > Cabergoline Therapy for Cushing Disease Throughout Pregnancy

ACOG MEMBER SUBSCRIPTION ACCESS

If you are an ACOG Fellow and have not logged in or registered to Obstetrics & Gynecology, please follow these step-by-step instructions to access journal content with your member subscription.

Obstetrics & Gynecology:
doi: 10.1097/AOG.0b013e31829e398a
Case Report

Cabergoline Therapy for Cushing Disease Throughout Pregnancy

Woo, Irene MD; Ehsanipoor, Robert M. MD

Collapse Box

Abstract

BACKGROUND: Cushing disease during pregnancy is rare and is associated with significant maternal and fetal morbidity and mortality. Transsphenoidal pituitary surgery is the first-line therapy; however, in cases of failed surgery or in patients who are not surgical candidates, medical therapy has been used to control symptoms.

CASE: A 29-year-old woman with Cushing disease and a noncurative transsphenoidal pituitary surgery was successfully treated with cabergoline, a dopamine agonist. After approximately 1 year of therapy, she became pregnant. She was maintained on high-dose cabergoline throughout her pregnancy and had an uncomplicated antenatal course. She went into spontaneous labor at 38 weeks of gestation and delivered a healthy female neonate.

CONCLUSION: Cabergoline can be used to manage Cushing disease successfully during pregnancy with an opportunity for a favorable outcome.

© 2013 by The American College of Obstetricians and Gynecologists.

Login

 

Looking for ABOG articles? Visit our ABOG MOC II collection. The selected Green Journal articles are free through the end of the calendar year.

ACOG MEMBER SUBSCRIPTION ACCESS

If you are an ACOG Fellow and have not logged in or registered to Obstetrics & Gynecology, please follow these step-by-step instructions to access journal content with your member subscription.

Article Tools

Share

Article Level Metrics